Transcription Factors Synergistically Activated at the Crossing of the Restriction Point between G1 and S Cell Cycle Phases. Pathologic Gate Opening during Multi-Hit Malignant Transformation

Transcription factors (TFs) represent key regulators of gene-expression patterns controlling cell behavior. TFs are active at nuclear – chromatin levels. TFs do not act in isolation; small sets of TFs cooperate toward the transcription of sets of mRNAs and consequently the translation of new proteins (the molecular phenotypes of a cell). Most TFs are activated through a cascade of biochemical reactions mediated by receptors expressed on the target cell surface. Nuclear Receptors (NRs) are transcription factors activated instead by small hydrophobic molecules capable of crossing the plasma membrane. The convergence of different pathways on TFs and their posttranslational modifications ensure that the external stimuli generate appropriate and integrated responses. The reconstruction of the molecular anatomy of these pathways through Molecular Interactions Maps (MIMs) can depict these intricate interactions. A mathematical modeling approach simulates/mimics their mechanism of action in normal and pathological conditions. We can simulate the effect of virtual hits in neoplastic transformation as mutations/alterations in these pathways. We can also simulate the effect of targeted inhibitors on these deregulated pathways. This strategy can help to guide an appropriate combination of targeted drugs in the treatment of a cancer patient, a major innovative perspective of incoming years.

[1]  Silvio Parodi,et al.  Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.

[2]  Bert Vogelstein,et al.  The Path to Cancer --Three Strikes and You're Out. , 2015, The New England journal of medicine.

[3]  T. M. Harrison,et al.  Potentially biogenic carbon preserved in a 4.1 billion-year-old zircon , 2015, Proceedings of the National Academy of Sciences.

[4]  M. Nowak,et al.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.

[5]  Hans Clevers,et al.  Sequential cancer mutations in cultured human intestinal stem cells , 2015, Nature.

[6]  Takanori Kanai,et al.  Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids , 2015, Nature Medicine.

[7]  T. Yap,et al.  Combining targeted therapeutics in the era of precision medicine , 2015, British Journal of Cancer.

[8]  Annalisa Barla,et al.  Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies , 2014, Oncotarget.

[9]  Sreeurpa Ray,et al.  The Cell: A Molecular Approach , 1996 .

[10]  A. Bardelli,et al.  Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.

[11]  T. Filtz,et al.  Regulation of transcription factor activity by interconnected post-translational modifications. , 2014, Trends in pharmacological sciences.

[12]  J. Slingerland,et al.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy , 2013, Nature Reviews Cancer.

[13]  J. Slingerland,et al.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy , 2013, Nature Reviews Cancer.

[14]  Ariana Peck,et al.  Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers , 2013, Nature.

[15]  J. Skotheim,et al.  Control of cell cycle transcription during G1 and S phases , 2013, Nature Reviews Molecular Cell Biology.

[16]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[17]  C. Glass,et al.  Signaling by nuclear receptors. , 2001, Cold Spring Harbor perspectives in biology.

[18]  Annalisa Barla,et al.  Parameter space exploration within dynamic simulations of signaling networks. , 2012, Mathematical biosciences and engineering : MBE.

[19]  J. Massagué TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[20]  Kevin Y. Yip,et al.  Understanding transcriptional regulation by integrative analysis of transcription factor binding data , 2012, Genome research.

[21]  Scott A. Busby,et al.  Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. , 2012, Chemistry & biology.

[22]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[23]  Hans Clevers,et al.  Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.

[24]  Hans Clevers,et al.  Isolation and in vitro expansion of human colonic stem cells , 2011, Nature Medicine.

[25]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[26]  D. A. Foster,et al.  Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s). , 2010, Genes & cancer.

[27]  Jarosław Młynarczuk,et al.  The role of the orphan receptor SF-1 in the development and function of the ovary. , 2010, Reproductive biology.

[28]  S Parodi,et al.  Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results. , 2010, Current cancer drug targets.

[29]  Albertha J. M. Walhout,et al.  The interplay between transcription factors and microRNAs in genome‐scale regulatory networks , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[30]  Juan M. Vaquerizas,et al.  A census of human transcription factors: function, expression and evolution , 2009, Nature Reviews Genetics.

[31]  Yanhong Shi,et al.  Orphan nuclear receptors in drug discovery. , 2007, Drug discovery today.

[32]  Vincent Laudet,et al.  Overview of Nomenclature of Nuclear Receptors , 2006, Pharmacological Reviews.

[33]  J. Weinstein,et al.  Depicting combinatorial complexity with the molecular interaction map notation , 2006, Molecular systems biology.

[34]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[35]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[36]  J. Weinstein,et al.  Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. , 2005, Molecular biology of the cell.

[37]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[38]  K. Helin,et al.  E2F target genes: unraveling the biology. , 2004, Trends in biochemical sciences.

[39]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[40]  Weiya Ma,et al.  Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. , 2004, Cancer research.

[41]  Richard A Gibbs,et al.  Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome. , 2004, Genome research.

[42]  John N Weinstein,et al.  Molecular Interaction Maps--A Diagrammatic Graphical Language for Bioregulatory Networks , 2004, Science's STKE.

[43]  J. Boonstra Progression through the G1‐phase of the on‐going cell cycle , 2003, Journal of cellular biochemistry.

[44]  Steven F. Dowdy,et al.  Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes , 2002 .

[45]  Ken Yagi,et al.  c-myc Is a Downstream Target of the Smad Pathway* 210 , 2002, The Journal of Biological Chemistry.

[46]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[47]  J. Olefsky,et al.  Nuclear Receptor Minireview Series* , 2001, The Journal of Biological Chemistry.

[48]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[49]  K. Kohn Molecular interaction map of the mammalian cell cycle control and DNA repair systems. , 1999, Molecular biology of the cell.

[50]  Bert Vogelstein,et al.  Gatekeepers and caretakers , 1997, Nature.

[51]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[52]  D. Reisman,et al.  Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. , 1995, Oncogene.

[53]  I. McEwan The Nuclear Receptor Superfamily at Thirty. , 2016, Methods in molecular biology.

[54]  L. Tortolina,et al.  Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. , 2016, Methods in molecular biology.

[55]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[56]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[57]  Steven F Dowdy,et al.  Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. , 2002, Current opinion in genetics & development.

[58]  H. Lodish,et al.  RNA Polymerase II Transcription-Initiation Complex , 2000 .